Search Results - "SANTINAMI, M"

Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients by Parmiani, G., Castelli, C., Pilla, L., Santinami, M., Colombo, M.P., Rivoltini, L.

“…Granulocyte-macrophage colony-stimulating factor (GM-CSF) has been and is still widely used as an adjuvant in clinical trials of vaccination with autologous…”
Get full text

Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study by Di Giacomo, A.M., Ascierto, P.A., Queirolo, P., Pilla, L., Ridolfi, R., Santinami, M., Testori, A., Simeone, E., Guidoboni, M., Maurichi, A., Orgiano, L., Spadola, G., Del Vecchio, M., Danielli, R., Calabrò, L., Annesi, D., Giannarelli, D., Maccalli, C., Fonsatti, E., Parmiani, G., Maio, M.

“…Long-term analysis of the NIBIT-M1 trial continues to demonstrate efficacy of the combination of ipilimumab and fotemustine in metastatic melanoma patients…”
Get full text

NFATc2 is an intrinsic regulator of melanoma dedifferentiation by Perotti, V, Baldassari, P, Molla, A, Vegetti, C, Bersani, I, Maurichi, A, Santinami, M, Anichini, A, Mortarini, R

“…Melanoma dedifferentiation, characterized by the loss of MITF and MITF regulated genes and by upregulation of stemness markers as CD271, is implicated in…”
Get full text

Correction to: NFATc2 is an intrinsic regulator of melanoma dedifferentiation by Perotti, V., Baldassari, P., Molla, A., Vegetti, C., Bersani, I., Maurichi, A., Santinami, M., Anichini, A., Mortarini, R.

“…In Fig. 6e, the authors noticed that wrong blots for MITF, MART-1 expression/modulation, and for β-actin were presented, due to the similarity with experiments…”
Get full text

Quality of Surgery and Outcome in Extra-Abdominal Aggressive Fibromatosis: A Series of Patients Surgically Treated at a Single Institution by GRONCHI, A, CASALI, P. G, ROSAI, J, MARIANI, L, LO VULLO, S, COLECCHIA, M, LOZZA, L, BERTULLI, R, FIORE, M, OLMI, P, SANTINAMI, M

“…To explore prognostic factors in surgically treated aggressive fibromatosis (extra-abdominal desmoid tumor). A total of 203 consecutive patients treated with…”
Get full text

Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600–mutant stage III melanoma by Long, G.V., Hauschild, A., Santinami, M., Atkinson, V.G., Mandala, M., Chiarion-Sileni, V., Larkin, J., Robert, C., Schadendorf, D., Dasgupta, K., Shilkrut, M., Garrett, J., Brase, J.C., Kefford, R., Kirkwood, J.M., Dummer, R.

Get full text

The number of excised lymph nodes is associated with survival of melanoma patients with lymph node metastasis by Rossi, C.R., Mozzillo, N., Maurichi, A., Pasquali, S., Quaglino, P., Borgognoni, L., Solari, N., Piazzalunga, D., Mascheroni, L., Giudice, G., Mocellin, S., Patuzzo, R., Caracò, C., Ribero, S., Marone, U., Santinami, M.

“…Although the number of excised LNs has been associated with patient prognosis in many solid tumors, this association has not been widely investigated in…”
Get full text

Prognostic Factors in Merkel Cell Carcinoma Patients Undergoing Sentinel Node Biopsy by Mattavelli, Ilaria, MD, Patuzzo, Roberto, MD, Torri, Valter, PhD, Gallino, Gianfranco, MD, Maurichi, Andrea, MD, Lamera, Mauro, MD, Valeri, Barbara, MD, Bolzonaro, Elisa, MD, Barbieri, Consuelo, MD, Tolomio, Elena, MD, Moglia, Daniele, MD, Nespoli, Angelo Maria, MD, Galeone, Carlotta, PhD, Saw, Robyn, MD, Santinami, Mario, MD

“…ABSTRACT Introduction Debate remains about prognostic factors in primary Merkel cell carcinoma (MCC). We investigated clinicopathological factors as…”
Get full text

Estimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trial by Dummer, R., Schadendorf, D., Hauschild, A., Santinami, M., Atkinson, V.G., Mandala, M., Chiarion Sileni, V., Larkin, J., Nyakas, M.S., Dutriaux, C., Haydon, A., Mortier, L., Robert, C., Schachter, J., Feng, X., de Jong, E., Mookerjee, B., Kefford, R., Kirkwood, J.M., Long, G.V.

Get full text

Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial by Atkinson, V.G., Hauschild, A., Santinami, M., Mandala, M., Chiarion Sileni, V., Larkin, J., Nyakas, M.S., Dutriaux, C., Haydon, A., Mortier, L., Robert, C., Schachter, J., Schadendorf, D., Feng, X., de Jong, E., Mookerjee, B., Kefford, R., Dummer, R., Kirkwood, J.M., Long, G.V.

Get full text

Acral lentiginous melanoma histotype predicts outcome in clinical stage I-II melanoma patients: an International multicenter study by Mandalà, M, Rutkowski, P, Galli, F, Patuzzo, R, De Giorgi, V, Rulli, E, Gianatti, A, Valeri, B, Merelli, B, Szumera-Ciećkiewicz, A, Massi, D, Maurichi, A, Teterycz, P, Santinami, M

“…In the American Joint Committee on Cancer (AJCC) classification, acral lentiginous melanoma (ALM) histotype ALM is not included as an independent prognostic…”
Get full text

Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial by Cascinelli, N, Morabito, A, Santinami, M, MacKie, RM, Belli, F

“…The use of elective regional node dissection in patients with cutaneous melanoma without any clinical evidence of metastatic spread is still debated. Our aim…”
Get full text

Chordoma: natural history and results in 28 patients treated at a single institution by Baratti, D, Gronchi, A, Pennacchioli, E, Lozza, L, Colecchia, M, Fiore, M, Santinami, M

“…The natural history of chordoma is characterized by a high failure rate and a poor functional outcome. The purpose of this study was to review the long-term…”
Get full text

3321 The role of sentinel lymph node biopsy in Merkel Cell Carcinoma: Analysis of 64 patients from a single institution by Mattavelli, I, Maurichi, A, Patuzzo, R, Gallino, G, Ruggeri, R, Tolomio, E, Nicolò, G, Santinami, M

Get full text

Factors predictive of pelvic lymph node involvement and outcomes in melanoma patients with metastatic sentinel lymph node of the groin: A multicentre study by Mozzillo, N, Pasquali, S, Santinami, M, Testori, A, Di Marzo, M, Crispo, A, Patuzzo, R, Verrecchia, F, Botti, G, Montella, M, Rossi, C.R, Caracò, C

“…Abstract Introduction The optimal extent of the groin lymph node (LN) dissection for melanoma patients with positive sentinel LN biopsy is still debated and no…”
Get full text

Micro-melanoma detection: a clinical study on 206 consecutive cases of pigmented skin lesions with a diameter ≤ 3 mm by Bono, A., Tolomio, E., Trincone, S., Bartoli, C., Tomatis, S., Carbone, A., Santinami, M.

“…Summary Background  Very small pigmented lesions may represent an important diagnostic challenge to the clinician. Objectives  The aim of the present study was…”
Get full text

Multispectral imaging and artificial neural network: mimicking the management decision of the clinician facing pigmented skin lesions by Carrara, M, Bono, A, Bartoli, C, Colombo, A, Lualdi, M, Moglia, D, Santoro, N, Tolomio, E, Tomatis, S, Tragni, G, Santinami, M, Marchesini, R

“…Various instruments based on acquisition and elaboration of images of pigmented skin lesions have been developed in an attempt to in vivo establish whether a…”
Get more information

387. Detection of clinical occult lymph node metastases by lymphoscintigraphy and sentinel node biopsy in anorectal melanoma patients by Gallino, G, Patuzzo, R, Maurichi, A, Ruggeri, R, Barbieri, C, Mattavelli, I, Niccolò, G, Santinami, M

Get full text

Differences in clinicopathological features and distribution of risk factors in Italian melanoma patients by Fava, P, Astrua, C, Chiarugi, A, Crocetti, E, Pimpinelli, N, Fargnoli, M C, Maurichi, A, Rubegni, P, Manganoni, A M, Bottoni, U, Catricalà, C, Cavicchini, S, Santinami, M, Alaibac, M, Annetta, A, Borghi, A, Calzavara Pinton, P, Capizzi, R, Clerico, R, Colombo, E, Corradin, M T, De Simone, P, Fantini, F, Ferreli, C, Filosa, G, Girgenti, V, Giulioni, E, Guarneri, C, Lamberti, A, Lisi, P, Nardini, P, Papini, M, Peris, K, Pizzichetta, M A, Salvini, C, Savoia, P, Strippoli, D, Tolomio, E, Tomassini, M A, Vena, G A, Zichichi, L, Patrizi, A, Argenziano, G, Simonacci, M, Quaglino, P

“…No studies are available in the literature on the distribution of different melanoma features and risk factors in the Italian geographical areas. To identify…”
Get more information

9305 ORAL A Phase II Study Combining Ipilimumab and Fotemustine in Patients With Metastatic Melanoma – the NIBIT-M1 Trial by Pi Giacomo, A.M, Ascierto, P.A, Pittiglio, E, Queirolo, P, Pilla, L, Ridolfi, R, Santinami, M, Testori, A, Parmiani, G, Maio, M

Get full text